Navigation Links
Exosome Diagnostics and QIAGEN Expand Collaboration to Develop Non-Invasive Biofluid Diagnostic for Lung Cancer
Date:1/13/2014

NEW YORK, Jan. 13, 2014 /PRNewswire/ -- Exosome Diagnostics today announced an expansion of its strategic collaboration with QIAGEN to develop non-invasive molecular diagnostics for use in detecting and monitoring actionable genetic mutations in lung cancer patients. In contrast with current molecular diagnostics requiring tissue biopsy, the focus will be to enable detection of well-understood cancer biomarkers in plasma, reducing both cost and patient risk.  Financial terms of the collaboration were not disclosed.

The program will focus on detection of known mutations associated with non-small cell lung cancer (NSCLC) and other malignancies that have the potential to be paired with targeted therapies. QIAGEN plans to submit the first diagnostic test developed under the collaboration to the Food and Drug Administration following clinical validation.

"The ability to perform molecular testing in blood represents an important advance in personalized medicine," said James McCullough, Chief Executive Officer of Exosome Diagnostics. "QIAGEN is the ideal partner to bring robust, regulated exosome technology products to the global clinical market place."   

Exosome Diagnostics' proprietary technology is focused on rapid, robust isolation of clinically actionable genetic biomarkers from blood, urine and cerebrospinal fluid for diagnosis, monitoring and companion diagnostic applications. The Company's clinical in vitro diagnostic products are designed to operate on widely available sequencing and PCR instruments. Exosome Diagnostics intends to launch the first in a series of blood-based mutation diagnostics in its CLIA laboratory beginning in 2014. 

Exosomes are the messenger packages in a fundamental biological communication system that transmits genetic instructions from cell to cell. The unique technology developed by Exosome Diagnostics allows non-invasive detection of key disease associated gene mutations and gene expressions in blood, urine and cerebrospinal fluid without the need for a surgical tissue biopsy.

About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are packaged and shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, disease-specific nucleic acids. The company's proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The company is commercializing in vitro diagnostic tests for use in personalized medicine and real-time monitoring of disease. For more information, please visit www.exosomedx.com.

 


'/>"/>
SOURCE Exosome Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cedars-Sinai Medical Center to Use Exosome Diagnostics Exosome RNA Biofluid Kits in Neo-Natal Setting and Cancer for Development of Personalized Medicine Diagnostics
2. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
3. Exosome Diagnostics Names Kapil Dhingra Chairman of the Board of Directors
4. ResearchMoz.us: MicroRNAs and Exosomes Market Report 2012 - Industry Research Report
5. Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
6. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
7. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
8. UC San Francisco and Quest Diagnostics Launch Collaboration to Advance the Field of Precision Medicine
9. Life Technologies to Provide Ion Torrent Sequencing Platform to Quest Diagnostics for Development of New Molecular Tests
10. Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics
11. Molecular Diagnostics Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):